490 related articles for article (PubMed ID: 32690069)
21. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K
J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625
[TBL] [Abstract][Full Text] [Related]
22. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer.
Martínez-Pérez C; Turnbull AK; Kay C; Dixon JM
Expert Rev Anticancer Ther; 2023 Jan; 23(1):67-86. PubMed ID: 36633402
[TBL] [Abstract][Full Text] [Related]
24. Endocrine therapy as adjuvant or neoadjuvant therapy for breast cancer: selecting the best agents, the timing and duration of treatment.
Li JJ; Shao ZM
Chin Clin Oncol; 2016 Jun; 5(3):40. PubMed ID: 27164856
[TBL] [Abstract][Full Text] [Related]
25. Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer.
Reinert T; Gonçalves R; Ellis MJ
Curr Treat Options Oncol; 2018 Apr; 19(5):23. PubMed ID: 29663173
[TBL] [Abstract][Full Text] [Related]
26. Invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved.
Saita C; Goto R; Aruga T; Idera N; Honda Y; Horiguchi K; Miyamoto H; Horiguchi S; Yamashita T; Kuroi K
BMC Res Notes; 2016 Jan; 9():46. PubMed ID: 26813772
[TBL] [Abstract][Full Text] [Related]
27. [Neoadjuvant antihormonal treatment of women with breast cancer].
Tuxen MK; Kamby C; Nielsen DL
Ugeskr Laeger; 2007 Sep; 169(37):3077-81. PubMed ID: 17877952
[TBL] [Abstract][Full Text] [Related]
28. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
Novoa Vargas A; Font López KC; Amador DD
Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
[TBL] [Abstract][Full Text] [Related]
29. The Landmark Series: Neoadjuvant Endocrine Therapy for Breast Cancer.
Weiss A; King TA; Mittendorf EA
Ann Surg Oncol; 2020 Sep; 27(9):3393-3401. PubMed ID: 32591951
[TBL] [Abstract][Full Text] [Related]
30. Endocrine therapy for early breast cancer.
Hussain SA; Williams S; Stevens A; Rea DW
Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
[TBL] [Abstract][Full Text] [Related]
31. [NEOADJUVANT TREATMENT OF LOCALLY ADVANCED ESTROGEN/PROGESTERONE POSITIVE, HER2NEU NEGATIVE BREAST CANCER].
Friedman NS; Shaham L; Sharon N; Barlev C
Harefuah; 2020 May; 159(5):370-375. PubMed ID: 32431130
[TBL] [Abstract][Full Text] [Related]
32. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Winer EP; Hudis C; Burstein HJ; Wolff AC; Pritchard KI; Ingle JN; Chlebowski RT; Gelber R; Edge SB; Gralow J; Cobleigh MA; Mamounas EP; Goldstein LJ; Whelan TJ; Powles TJ; Bryant J; Perkins C; Perotti J; Braun S; Langer AS; Browman GP; Somerfield MR
J Clin Oncol; 2005 Jan; 23(3):619-29. PubMed ID: 15545664
[TBL] [Abstract][Full Text] [Related]
33. [Neoadjuvant endocrine therapy for postmenopausal estrogen receptor-positive patients with breast cancer].
Zhang B
Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):241-4. PubMed ID: 21575491
[No Abstract] [Full Text] [Related]
34. Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?
van Dam PA; van Dam VC; Altintas S; Papadimitriou K; Rolfo C; Trinh XB
Eur J Surg Oncol; 2016 Mar; 42(3):333-42. PubMed ID: 26776766
[TBL] [Abstract][Full Text] [Related]
35. Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer.
da Silva LR; de Andrade CA; Brenelli F; Ramalho S; Reinert T; de Souza ABA; da Silva AER; de Paula Leite Kraft MB; de Vasconcelos VCA; Frasson AL; Torresan RZ; Cabello C; Ellis MJ; Zeferino LC
Breast Cancer Res Treat; 2021 Apr; 186(3):753-760. PubMed ID: 33543355
[TBL] [Abstract][Full Text] [Related]
36. High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer.
Endo Y; Toyama T; Takahashi S; Sugiura H; Yoshimoto N; Iwasa M; Kobayashi S; Fujii Y; Yamashita H
Int J Clin Oncol; 2011 Oct; 16(5):512-8. PubMed ID: 21431343
[TBL] [Abstract][Full Text] [Related]
37. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
38. Sequencing of hormonal therapy in postmenopausal women with metastatic breast cancer.
Parker LM
Clin Ther; 2002; 24 Suppl C():C43-57. PubMed ID: 12117075
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.
Dixon JM; Jackson J; Renshaw L; Miller WR
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):295-9. PubMed ID: 14623524
[TBL] [Abstract][Full Text] [Related]
40. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
